1、 2015 1 2017 1 74 , , , (n=40) , (n=34) , CA125 (P0.05) , , (P0.05) , 1.2 , 2 cm , 7-14d 135-175 mg/m 75 mg/m , 3 1 , 8 1 3 5d , 400- , 3500 ml , 60min, 1 135-175 mg/m ( Hospira Australia Pty Ltd, H20090175) , , 30 , 2 70-75 mg/m ( , H20040813) , 3 CA125 , , 1-3 , 1.3 SPSS 20.0 , , n (%) , , P0.05 2
2、 2.1 CA125 1 1 CA125 2.2 1-3 2 2 1-3 n (%) 3 , , , , , , , , , 2 , , , , , G2 M , , 44%3 , 28%4, , , , , 17-663 5 , , , 40- , 45.7- , , , : (1) , ; ; NO , , , , CDDP , , 48 , , CA125 , (P0.05) ; 1 88.2%, 3 76.5%, (P0.05) , , 1 , , , . J. , 2016, 6 (4) :291-295. 2 , , , . J. , 2013, 36 (3) :10-13. 3 . J. , 2017, 23 (8) :86-87. 4 , , , . J. , 2015, 25 (11) :80-82. 5 , , , . J. , 2015, 35 (17) :4883-4884.